Fakher Rahim

@alnoor university

Department of Medical Laboratory Technologies,
Fakher Rahim



                 

https://researchid.co/bioinfo2003

RESEARCH, TEACHING, or OTHER INTERESTS

Biotechnology, Molecular Medicine, Genetics, Structural Biology

349

Scopus Publications

114613

Scholar Citations

93

Scholar h-index

312

Scholar i10-index

Scopus Publications

  • A meta-analysis of Preclinical Studies About The Effect of Spray-dried Porcine Plasma on Microbiota Composition
    Momunova Abdykerimovna, Fakher Rahim, Lyailya Alekesheva, Toguzbaeva Karlygash, Sokolov Dmitriy Konstantinovich, Kenesh Dzhusupov, and Abzal Zhumagaliuly

    Egyptian Knowledge Bank
    M ICROORGANISMS in the gut microbiota have developed alongside the host for thousands of years. Spray-dried porcine plasma (SDPP) increases development and immunity, making it a promising antibiotic replacement. In this systematic review and meta-analysis, we examined all available data on spray-dried porcine plasma’s immune response and microbiota composition alterations, which may affect antibacterial effectiveness. To achieve this goal, Cochrane central, ISI web of science (WOS), PubMed/Medline, Scopus, and EMBASE were systematically searched using standard terms. No language, study region, or research kind restrictions applied. Following the exclusion criteria, this meta-analysis included 11 papers on 474 animals’ important traits. Eleven studies involved 474 animals in this meta-analysis. The study involved eight pigs, three mice, one dog , bird, and fish. Firmicutes, Bacteroidetes , and other bacteria were more prevalent in SDPP-fed pig samples than in control diet samples. Proteobacteria, Tenericutes , and Actinobacteria were less common in SDPP-fed pig samples. SDPP did not affect growth performance measures compared to the control group. SDPP-exposed animals had higher Shannon and Simpson indices and more species, regardless of BW. In addition, treatment groups had similar colonic microbiota richness estimators (Chao 1). This study represents the first comprehensive meta-analysis to investigate the impact of SDPP s on immune response and microbiota composition alterations, which may affect antibacterial effectiveness in the peer-reviewed literature. The study’s findings demonstrated that the utilization of SDPP imposes little residual effects on the overall growth performance and increases the diversity and richness of bacterial communities, ultimately leading to alterations in the microbiota composition of the animals.

  • Global, regional, and national burden of stroke and its risk factors, 1990–2021: a systematic analysis for the Global Burden of Disease Study 2021
    Valery L Feigin, Melsew Dagne Abate, Yohannes Habtegiorgis Abate, Samar Abd ElHafeez, Foad Abd-Allah, Ahmed Abdelalim, Atef Abdelkader, Michael Abdelmasseh, Sherief Abd-Elsalam, Parsa Abdi,et al.

    Elsevier BV

  • Global burden of bacterial antimicrobial resistance 1990–2021: a systematic analysis with forecasts to 2050
    Mohsen Naghavi, Stein Emil Vollset, Kevin S Ikuta, Lucien R Swetschinski, Authia P Gray, Eve E Wool, Gisela Robles Aguilar, Tomislav Mestrovic, Georgia Smith, Chieh Han,et al.

    Elsevier BV

  • Global, regional, and national incidence and mortality burden of non-COVID-19 lower respiratory infections and aetiologies, 1990–2021: a systematic analysis from the Global Burden of Disease Study 2021
    Rose Grace Bender, Sarah Brooke Sirota, Lucien R Swetschinski, Regina-Mae Villanueva Dominguez, Amanda Novotney, Eve E Wool, Kevin S Ikuta, Avina Vongpradith, Emma Lynn Best Rogowski, Matthew Doxey,et al.

    Elsevier BV

  • Global pattern, trend, and cross-country inequality of early musculoskeletal disorders from 1990 to 2019, with projection from 2020 to 2050
    Yingzhao Jin, Cui Guo, Mohammadreza Abbasian, Mitra Abbasifard, J. Haxby Abbott, Auwal Abdullahi, Aidin Abedi, Hassan Abidi, Hassan Abolhassani, Eman Abu-Gharbieh,et al.

    Elsevier BV

  • Global estimates on the number of people blind or visually impaired by cataract: a meta-analysis from 2000 to 2020
    Konrad Pesudovs, Van Charles Lansingh, John H. Kempen, Ian Tapply, Arthur G. Fernandes, Maria V. Cicinelli, Alessandro Arrigo, Nicolas Leveziel, Paul Svitil Briant, Theo Vos,et al.

    Springer Science and Business Media LLC
    Abstract Background To estimate global and regional trends from 2000 to 2020 of the number of persons visually impaired by cataract and their proportion of the total number of vision-impaired individuals. Methods A systematic review and meta-analysis of published population studies and gray literature from 2000 to 2020 was carried out to estimate global and regional trends. We developed prevalence estimates based on modeled distance visual impairment and blindness due to cataract, producing location-, year-, age-, and sex-specific estimates of moderate to severe vision impairment (MSVI presenting visual acuity <6/18, ≥3/60) and blindness (presenting visual acuity <3/60). Estimates are age-standardized using the GBD standard population. Results In 2020, among overall (all ages) 43.3 million blind and 295 million with MSVI, 17.0 million (39.6%) people were blind and 83.5 million (28.3%) had MSVI due to cataract blind 60% female, MSVI 59% female. From 1990 to 2020, the count of persons blind (MSVI) due to cataract increased by 29.7%(93.1%) whereas the age-standardized global prevalence of cataract-related blindness improved by −27.5% and MSVI increased by 7.2%. The contribution of cataract to the age-standardized prevalence of blindness exceeded the global figure only in South Asia (62.9%) and Southeast Asia and Oceania (47.9%). Conclusions The number of people blind and with MSVI due to cataract has risen over the past 30 years, despite a decrease in the age-standardized prevalence of cataract. This indicates that cataract treatment programs have been beneficial, but population growth and aging have outpaced their impact. Growing numbers of cataract blind indicate that more, better-directed, resources are needed to increase global capacity for cataract surgery.

  • Global estimates on the number of people blind or visually impaired by age-related macular degeneration: a meta-analysis from 2000 to 2020
    , João M. Furtado, Jost B. Jonas, Ian Tapply, Arthur G. Fernandes, Maria Vittoria Cicinelli, Alessandro Arrigo, Nicolas Leveziel, Serge Resnikoff, Hugh R. Taylor,et al.

    Springer Science and Business Media LLC
    Abstract Background We aimed to update estimates of global vision loss due to age-related macular degeneration (AMD). Methods We did a systematic review and meta-analysis of population-based surveys of eye diseases from January, 1980, to October, 2018. We fitted hierarchical models to estimate the prevalence of moderate and severe vision impairment (MSVI; presenting visual acuity from <6/18 to 3/60) and blindness ( < 3/60) caused by AMD, stratified by age, region, and year. Results In 2020, 1.85 million (95%UI: 1.35 to 2.43 million) people were estimated to be blind due to AMD, and another 6.23 million (95%UI: 5.04 to 7.58) with MSVI globally. High-income countries had the highest number of individuals with AMD-related blindness (0.60 million people; 0.46 to 0.77). The crude prevalence of AMD-related blindness in 2020 (among those aged ≥ 50 years) was 0.10% (0.07 to 0.12) globally, and the region with the highest prevalence of AMD-related blindness was North Africa/Middle East (0.22%; 0.16 to 0.30). Age-standardized prevalence (using the GBD 2019 data) of AMD-related MSVI in people aged ≥ 50 years in 2020 was 0.34% (0.27 to 0.41) globally, and the region with the highest prevalence of AMD-related MSVI was also North Africa/Middle East (0.55%; 0.44 to 0.68). From 2000 to 2020, the estimated crude prevalence of AMD-related blindness decreased globally by 19.29%, while the prevalence of MSVI increased by 10.08%. Conclusions The estimated increase in the number of individuals with AMD-related blindness and MSVI globally urges the creation of novel treatment modalities and the expansion of rehabilitation services.

  • Correction to: Global estimates on the number of people blind or visually impaired by cataract_ a meta-analysis from 2000 to 2020 (Eye, (2024), 10.1038/s41433-024-02961-1)
    , Konrad Pesudovs, Van Charles Lansingh, John H. Kempen, Ian Tapply, Arthur G. Fernandes, Maria Vittoria Cicinelli, Alessandro Arrigo, Nicolas Leveziel, Serge Resnikoff,et al.

    Springer Science and Business Media LLC

  • Global estimates on the number of people blind or visually impaired by glaucoma: A meta-analysis from 2000 to 2020
    , Rupert R. A. Bourne, Jost B. Jonas, David Friedman, Vinay Nangia, Alain Bron, Ian Tapply, Arthur G. Fernandes, Maria Vittoria Cicinelli, Alessandro Arrigo,et al.

    Springer Science and Business Media LLC
    Abstract Objectives To estimate global and regional trends from 2000 to 2020 of the number of persons visually impaired by glaucoma and their proportion of the total number of vision-impaired individuals. Methods A systematic review and meta-analysis of published population studies and grey literature from 2000 to 2020 was carried out to estimate global and regional trends in number of people with vision loss due to glaucoma. Moderate or severe vision loss (MSVI) was defined as visual acuity of 6/60 or better but <6/18 (moderate) and visual acuity of 3/60 or better but <6/60 (severe vision loss). Blindness was defined as presenting visual acuity <3/60. Results Globally, in 2020, 3.61 million people were blind and nearly 4.14 million were visually impaired by glaucoma. Glaucoma accounted for 8.39% (95% uncertainty intervals [UIs]: 6.54, 10.29) of all blindness and 1.41% (95% UI: 1.10, 1.75) of all MSVI. Regionally, the highest proportion of blindness relating to glaucoma was found in high-income countries (26.12% [95% UI: 20.72, 32.09]), while the region with the highest age-standardized prevalence of glaucoma-related blindness and MSVI was Sub-Saharan Africa. Between 2000 and 2020, global age-standardized prevalence of glaucoma-related blindness among adults ≥50 years decreased by 26.06% among males (95% UI: 25.87, 26.24), and by 21.75% among females (95% UI: 21.54, 21.96), while MSVI due to glaucoma increased by 3.7% among males (95% UI: 3.42, 3.98), and by 7.3% in females (95% UI: 7.01, 7.59). Conclusions Within the last two decades, glaucoma has remained a major cause of blindness globally and regionally.

  • Global, regional, and national age-specific progress towards the 2020 milestones of the WHO End TB Strategy: a systematic analysis for the Global Burden of Disease Study 2021
    Jorge R Ledesma, Jianing Ma, Meixin Zhang, Ann V L Basting, Huong Thi Chu, Avina Vongpradith, Amanda Novotney, Kate E LeGrand, Yvonne Yiru Xu, Xiaochen Dai,et al.

    Elsevier BV

  • The Impact of Human Cystic Echinococcosis in the Central Asian Region, 1990-2019
    Fakher Rahim, Karlygash Toguzbaeva, and Kenesh O. Dzhusupov

    Galenos Yayinevi
    Objective This research aims to update knowledge on the regional and national sickness burden attributable to cystic echinococcosis (CE) from 1990 to 2019, as well as epidemiology and disease control, with a particular emphasis on the People's Central Asian Regions. Methods We calculated the morbidity, mortality, and disability-adjusted life years at the global, regional, and national levels for CE in all central Asian countries from 1990 to 2019, and we analyzed the association between GDP per capita and the disease burden of CE. Results In 2019, the three greatest numbers of CE cases were recorded in Kazakhstan [23986; 95% uncertainty interval (UI); 19796; 28908]; Uzbekistan (41079; 18351; 76048); and Tajikistan (10887; 4891; 20170) among all 9 countries. The three countries with the greatest ASIR of CE were estimated to be Kazakhstan (127.56; 95% UI: 105.34-153.8), Uzbekistan (123.53; 95% UI: 58.65-219.16), and Tajikistan (121.88; 58.57-213.93). Kyrgyzstan, Tajikistan, and Uzbekistan had the biggest increases (125%, 97%, and 83%, respectively) in the number of incident cases of CE, whereas Georgia, Kazakhstan, and Armenia saw the largest decreases (45%, 8%, and 3%, respectively). Conclusion To reduce the illness burden caused by CE, our findings may help public health professionals and policymakers design cost-benefit initiatives. To lessen the impact of CE on society, it is suggested that more money be given to the region's most endemic nations. Echinococcosis, cystic, negative health effects, life-years lost due to disability, rate of occurrence as a function of age, rate of death as a function of age.

  • Global burden and strength of evidence for 88 risk factors in 204 countries and 811 subnational locations, 1990–2021: a systematic analysis for the Global Burden of Disease Study 2021
    Michael Brauer, Gregory A Roth, Aleksandr Y Aravkin, Peng Zheng, Kalkidan Hassen Abate, Yohannes Habtegiorgis Abate, Cristiana Abbafati, Rouzbeh Abbasgholizadeh, Madineh Akram Abbasi, Mohammadreza Abbasian,et al.

    Elsevier BV

  • Burden of disease scenarios for 204 countries and territories, 2022–2050: a forecasting analysis for the Global Burden of Disease Study 2021
    Stein Emil Vollset, Hazim S Ababneh, Yohannes Habtegiorgis Abate, Cristiana Abbafati, Rouzbeh Abbasgholizadeh, Mohammadreza Abbasian, Hedayat Abbastabar, Abdallah H A Abd Al Magied, Samar Abd ElHafeez, Atef Abdelkader,et al.

    Elsevier BV

  • Global burden of 288 causes of death and life expectancy decomposition in 204 countries and territories and 811 subnational locations, 1990–2021: a systematic analysis for the Global Burden of Disease Study 2021
    Mohsen Naghavi, Kanyin Liane Ong, Amirali Aali, Hazim S Ababneh, Yohannes Habtegiorgis Abate, Cristiana Abbafati, Rouzbeh Abbasgholizadeh, Mohammadreza Abbasian, Mohsen Abbasi-Kangevari, Hedayat Abbastabar,et al.

    Elsevier BV

  • Global age-sex-specific mortality, life expectancy, and population estimates in 204 countries and territories and 811 subnational locations, 1950–2021, and the impact of the COVID-19 pandemic: a comprehensive demographic analysis for the Global Burden of Disease Study 2021
    Austin E Schumacher, Hmwe Hmwe Kyu, Amirali Aali, Cristiana Abbafati, Jaffar Abbas, Rouzbeh Abbasgholizadeh, Madineh Akram Abbasi, Mohammadreza Abbasian, Samar Abd ElHafeez, Michael Abdelmasseh,et al.

    Elsevier BV

  • Global fertility in 204 countries and territories, 1950–2021, with forecasts to 2100: a comprehensive demographic analysis for the Global Burden of Disease Study 2021
    N. V. Bhattacharjee, Austin E. Schumacher, Amirali Aali, Yohannes Habtegiorgis Abate, Rouzbeh Abbasgholizadeh, Mohammadreza Abbasian, M. Abbasi-Kangevari, Hedayat Abbastabar, S. ElHafeez, S. Abd-Elsalam,et al.



  • Global, regional, and national burden of disorders affecting the nervous system, 1990–2021: a systematic analysis for the Global Burden of Disease Study 2021
    Jaimie D Steinmetz, Katrin Maria Seeher, Nicoline Schiess, Emma Nichols, Bochen Cao, Chiara Servili, Vanessa Cavallera, Ewerton Cousin, Hailey Hagins, Madeline E Moberg,et al.

    Elsevier BV

  • A microchip for exosome isolation that can be impregnated with imatinib simultaneously: an in vitro analysis
    Amir Monfaredan, Fakher Rahim, Gholamreza Tavoosidana, Mohammad Hossein Modarressi, Alaviyehsadat Hosseininasab, Ali-Akbar Aghajani-Afrouzi, Mahdi Shafiee Sabet, and Elahe Motevaseli

    LLC Science and Innovations
    Background and Aims — Exosomes, which are tiny double-layered membranes originating from eukaryotic cells, have been recognized as a valuable natural vehicle for delivering substances because of their optimal size, compatibility with living organisms, strong structure, ability to carry a large amount of cargo, and capacity to be modified on their surface. Methods — Various strategies have been employed to isolate exosomes due to the challenges associated with maintaining their high purity. The current investigation utilized a soft lithography technique to fabricate channels for exosome separation, incorporating immunoaffinity capabilities. Both biochemical and biophysical assays were conducted to assess the quality of isolated exosomes from various sources (serum, cell supernatant, and urine) and compared with a commercially available kit. Results — The current investigation employed a microfluidic method to capture CD63-conjugated magnetic beads, resulting in a very effective separation of exosomes. Based on the data, there were no notable variations in miRNAs that were statistically significant. This demonstrates that the engineered chip successfully achieved the separation of the exosome while preserving the integrity of its nucleic acid components. Conclusion — The results shown that the current methodology effectively isolated exosomes with a high yield rate, purity, and minimal time requirement. The imatinib laden exosomes demonstrated anticancer efficacy against the KYO-1 cell line in all of their forms.




  • Retraction Note: Association of the corona virus (Covid-19) epidemic with environmental risk factors (Environmental Science and Pollution Research, (2023), 30, 21, (60314-60325), 10.1007/s11356-023-26647-5)
    Abdolkazem Neisi, Gholamreza Goudarzi, Mohammad Javad Mohammadi, Yasser Tahmasebi, Fakher Rahim, Zeinab Baboli, Mohsen Yazdani, Armin Sorooshian, Somayeh Alizade Attar, Kambiz Ahmadi Angali,et al.

    Springer Science and Business Media LLC

  • Global, regional, and national burden of upper respiratory infections and otitis media, 1990–2021: a systematic analysis from the Global Burden of Disease Study 2021
    Sarah Brooke Sirota, Matthew C Doxey, Regina-Mae Villanueva Dominguez, Rose Grace Bender, Avina Vongpradith, Samuel B Albertson, Amanda Novotney, Katrin Burkart, Austin Carter, Parsa Abdi,et al.

    Elsevier BV

  • Correction to: Intranasal Oxytocin for Patients With Autism Spectrum Disorder: A Comprehensive Meta-Analysis of Preclinical and Clinical Studies (Review Journal of Autism and Developmental Disorders, (2024), 10.1007/s40489-024-00428-3)
    Fakher Rahim, Nameer Hashim Qasim, Toguzbaeva Karlygash, Fariza Khozhamkul, Kenesh Dzhusupov, Ainur Tekmanova, and Kussaiynova Elmira

    Springer Science and Business Media LLC

  • Designing a microchip for exosome isolation with the ability to simultaneously impregnate it with imatinib: an in vitro analysis
    Amir Monfaredan, , Fakher Rahim, Kudaiberdi G. Kozhobekov, Gholamreza Tavoosidana, Mohammad H. Modarressi, Alaviyehsadat Hosseininasab, Ali-Akbar Aghajani-Afrouzi, Mahdi Sh. Sabet, Elahe Motevaseli,et al.

    Editorial Board of Journal Radioelectronics, Nanosystems, Information Technology RENSIT
    Exosomes, a small bilayer membrane derived from eukaryotic cells, have been identified as a useful natural delivery platform due to their suitable size, biocompatibility, structural stability, high loading capacity, and editable surface capability. Due to the difficulty of maintaining the highly pure exosome, several attempts have conducted the techniques for exosome isolation. In recent years, microstructures have found many applications in chemistry, biology, and medicine due to their high accuracy and low cost of materials. Soft lithography is a low-cost, fast, accurate, and yet widely used method of construction of Micron channels. In the present study, a soft lithography process has been performed to construct channels for exosome separation with immunoaffinity function. Both biochemical and biophysical categories tests were performed to examine the quality of extracted exosomes from different sources (serum, cell supernatant, and urine) and compared with the commercially available kit. Results showed that the current technique was capable to isolate exosomes with a high yield rate, purity, and low time consumption. All forms of the imatinib loaded exosomes exhibited the antitumor activity against KYO-1 cell line.

RECENT SCHOLAR PUBLICATIONS

  • A meta-analysis of Preclinical Studies About The Effect of Spray-dried Porcine Plasma on Microbiota Composition
    MA Abdykerimovna, F Rahim, L Alekesheva, T Karlygash, ...
    Egyptian Journal of Veterinary Sciences 56 (4), 679-690 2025

  • Global, regional, and national burden of stroke and its risk factors, 1990–2021: a systematic analysis for the Global Burden of Disease Study 2021
    VL Feigin, MD Abate, YH Abate, S Abd ElHafeez, F Abd-Allah, ...
    The Lancet Neurology 23 (10), 973-1003 2024

  • Global burden of bacterial antimicrobial resistance 1990–2021: a systematic analysis with forecasts to 2050
    M Naghavi, SE Vollset, KS Ikuta, LR Swetschinski, AP Gray, EE Wool, ...
    The Lancet 404 (10459), 1199-1226 2024

  • Simplifying IP multimedia systems by introducing next-generation networks with scalable architectures
    NH Qasim, DA Jumaa, F Rahim, AM Jawad, AM Khaleefah, G Zhyrov, ...
    Edelweiss Applied Science and Technology 8 (4), 2042-2054 2024

  • Natural language processing for healthcare: Applications, progress, and future directions
    F Rahim, NA Hameed, SA Salih, AM Jawad, HM Salman, ...
    Edelweiss Applied Science and Technology 8 (4), 2027-2041 2024

  • A comprehensive investigation of an LTE-enabled smart door system using the Arduino UNO
    NH Qasim, F Rahim, N Bodnar
    Edelweiss Applied Science and Technology 8 (4), 697-708 2024

  • Global, regional, and national burden of upper respiratory infections and otitis media, 1990–2021: a systematic analysis from the Global Burden of Disease Study 2021
    SB Sirota, MC Doxey, RMV Dominguez, RG Bender, A Vongpradith, ...
    The Lancet Infectious Diseases 2024

  • Correction to: Intranasal Oxytocin for Patients With Autism Spectrum Disorder: A Comprehensive Meta-Analysis of Preclinical and Clinical Studies
    F Rahim, NH Qasim, T Karlygash, F Khozhamkul, K Dzhusupov, ...
    Review Journal of Autism and Developmental Disorders, 1-1 2024

  • Strategies to Strengthen Iraq’s Primary Healthcare System: A Systematic Literature Review with Special Focus on Society 5
    F Rahim, T Karlygash, K Dzhusupov
    Authorea Preprints 2024

  • Publisher Correction: Global estimates on the number of people blind or visually impaired by cataract: a meta-analysis from 2000 to 2020 (Eye,(2024), 38, 11,(2156-2172), 10
    RRA Bourne, N Wang, YX Wang, M Tsilimbaris, F Topouzis, P Ramulu, ...
    Eye (Basingstoke) 38 (11), 2229-2231 2024

  • Global estimates on the number of people blind or visually impaired by cataract: a meta-analysis from 2000 to 2020
    Vision Loss Expert Group of the Global Burden of Disease Study
    Eye 38 (11), 2156 2024

  • COMPARATIVE CHARACTERISTICS OF THE CONDITION OF TISSUE UPPER RESPIRATORY TRACT IN CHILDREN WITH RESPIRATORY DISEASES LIVING IN KYRGYZSTAN, LOCATED AT DIFFERENT ALTITUDES ABOVE
    KN Ismailov ID, Kalmatov RK, Rahim F., Momunova AA
    The New Armenian Medical Journal 18 (3), 42-50 2024

  • CUBN GENE POLYMORPHISMS AND SUSCEPTIBILITY TO TYPE 2 DIABETES VERSUS TYPE 1 DIABETES. A SYSTEMATIC REVIEW
    DK Kalmatov RK, Rahim F., Akhunbaeva T., Toguzbaeva K.
    The New Armenian Medical Journal 18 (3), 4-12 2024

  • A prognostic model for use before elective surgery to estimate the risk of postoperative pulmonary complications (GSU-Pulmonary Score): a development and validation study in
    L Bravo, JFF Simes, VR Cardoso, A Adisa, ML Aguilera, A Arnaud, ...
    The Lancet Digital Health 6 (7), e507-e519 2024

  • Global pattern, trend, and cross-country inequality of early musculoskeletal disorders from 1990 to 2019, with projection from 2020 to 2050
    Y Jin, C Guo, M Abbasian, M Abbasifard, JH Abbott, A Abdullahi, A Abedi, ...
    Med 2024

  • The Impact of Human Cystic Echinococcosis in the Central Asian Region, 1990-2019
    F Rahim, K Toguzbaeva, KO Dzhusupov
    Trkiye Parazitolojii Dergisi 48 (2), 89-95 2024

  • Burden of disease scenarios for 204 countries and territories, 2022–2050: a forecasting analysis for the Global Burden of Disease Study 2021
    SE Vollset, HS Ababneh, YH Abate, C Abbafati, R Abbasgholizadeh, ...
    The Lancet 403 (10440), 2204-2256 2024

  • Global burden and strength of evidence for 88 risk factors in 204 countries and 811 subnational locations, 1990–2021: a systematic analysis for the Global Burden of Disease
    M Brauer, GA Roth, AY Aravkin, P Zheng, KH Abate, YH Abate, C Abbafati, ...
    The Lancet 403 (10440), 2162-2203 2024

  • Global burden of 288 causes of death and life expectancy decomposition in 204 countries and territories and 811 subnational locations, 1990–2021: a systematic analysis for the
    M Naghavi, KL Ong, A Aali, HS Ababneh, YH Abate, C Abbafati, ...
    The Lancet 403 (10440), 2100-2132 2024

  • Global age-sex-specific mortality, life expectancy, and population estimates in 204 countries and territories and 811 subnational locations, 1950–2021, and the impact of the
    AE Schumacher, HH Kyu, A Aali, C Abbafati, J Abbas, ...
    The Lancet 403 (10440), 1989-2056 2024

MOST CITED SCHOLAR PUBLICATIONS

  • Global, regional, and national incidence, prevalence, and years lived with disability for 354 diseases and injuries for 195 countries and territories, 1990–2017: a systematic
    SL James, D Abate, KH Abate, SM Abay, C Abbafati, N Abbasi, ...
    The Lancet 392 (10159), 1789-1858 2018
    Citations: 9582

  • Global burden of 369 diseases and injuries in 204 countries and territories, 1990–2019: a systematic analysis for the Global Burden of Disease Study 2019
    T Vos, SS Lim, C Abbafati, KM Abbas, M Abbasi, M Abbasifard, ...
    The lancet 396 (10258), 1204-1222 2020
    Citations: 8585

  • Global, regional, and national cancer incidence, mortality, years of life lost, years lived with disability, and disability-adjusted life-years for 32 cancer groups, 1990 to
    C Fitzmaurice, C Allen, RM Barber, L Barregard, ZA Bhutta, H Brenner, ...
    JAMA oncology 3 (4), 524-548 2017
    Citations: 8049

  • Global, regional, and national comparative risk assessment of 84 behavioural, environmental and occupational, and metabolic risks or clusters of risks for 195 countries and
    JD Stanaway, A Afshin, E Gakidou, SS Lim, D Abate, KH Abate, ...
    The Lancet 392 (10159), 1923-1994 2018
    Citations: 7631

  • Global, regional, and national age-sex-specific mortality for 282 causes of death in 195 countries and territories, 1980–2017: a systematic analysis for the Global Burden of
    GA Roth, D Abate, KH Abate, SM Abay, C Abbafati, N Abbasi, ...
    The lancet 392 (10159), 1736-1788 2018
    Citations: 7256

  • Global burden of cardiovascular diseases and risk factors, 1990–2019: update from the GBD 2019 study
    GA Roth, GA Mensah, CO Johnson, G Addolorato, E Ammirati, ...
    Journal of the American college of cardiology 76 (25), 2982-3021 2020
    Citations: 7244

  • Global, regional, and national sepsis incidence and mortality, 1990–2017: analysis for the Global Burden of Disease Study
    KE Rudd, SC Johnson, KM Agesa, KA Shackelford, D Tsoi, DR Kievlan, ...
    The Lancet 395 (10219), 200-211 2020
    Citations: 5140

  • Global, regional, and national age-sex specific all-cause and cause-specific mortality for 240 causes of death, 1990-2013: a systematic analysis for the Global Burden of
    M Correction Naghavi, H Wang, R Lozano, A Davis, X Liang, M Zhou, ...
    The Lancet 385 (9963), 117-171 2015
    Citations: 4753

  • Global, regional, and national burden of neurological disorders, 1990–2016: a systematic analysis for the Global Burden of Disease Study 2016
    VL Feigin, E Nichols, T Alam, MS Bannick, E Beghi, N Blake, ...
    The Lancet Neurology 18 (5), 459-480 2019
    Citations: 4401

  • Global, regional, and national disability-adjusted life-years (DALYs) for 359 diseases and injuries and healthy life expectancy (HALE) for 195 countries and territories, 1990
    HH Kyu, D Abate, KH Abate, SM Abay, C Abbafati, N Abbasi, ...
    The Lancet 392 (10159), 1859-1922 2018
    Citations: 4051

  • Alcohol use and burden for 195 countries and territories, 1990–2016: a systematic analysis for the Global Burden of Disease Study 2016
    MG Griswold, N Fullman, C Hawley, N Arian, SRM Zimsen, HD Tymeson, ...
    The Lancet 392 (10152), 1015-1035 2018
    Citations: 2998

  • Estimation of the global prevalence of dementia in 2019 and forecasted prevalence in 2050: an analysis for the Global Burden of Disease Study 2019
    E Nichols, JD Steinmetz, SE Vollset, K Fukutaki, J Chalek, F Abd-Allah, ...
    The Lancet Public Health 7 (2), e105-e125 2022
    Citations: 2441

  • Global, regional, and national burden of stroke and its risk factors, 1990–2019: a systematic analysis for the Global Burden of Disease Study 2019
    VL Feigin, BA Stark, CO Johnson, GA Roth, C Bisignano, GG Abady, ...
    The Lancet Neurology 20 (10), 795-820 2021
    Citations: 2016

  • Global, regional, and national burden of stroke and its risk factors, 1990–2019: a systematic analysis for the Global Burden of Disease Study 2019
    GBD 2019 Stroke Collaborators
    The Lancet. Neurology 20 (10), 795 2021
    Citations: 1916

  • Prevalence and attributable health burden of chronic respiratory diseases, 1990–2017: a systematic analysis for the Global Burden of Disease Study 2017
    JB Soriano, PJ Kendrick, KR Paulson, V Gupta, EM Abrams, RA Adedoyin, ...
    The Lancet Respiratory Medicine 8 (6), 585-596 2020
    Citations: 1632

  • Causes of blindness and vision impairment in 2020 and trends over 30 years, and prevalence of avoidable blindness in relation to VISION 2020: the Right to Sight: an analysis
    JD Steinmetz, RRA Bourne, PS Briant, SR Flaxman, HRB Taylor, ...
    The Lancet Global Health 9 (2), e144-e160 2021
    Citations: 1564

  • Global, regional, and national burden of stroke, 1990–2016: a systematic analysis for the Global Burden of Disease Study 2016
    CO Johnson, M Nguyen, GA Roth, E Nichols, T Alam, D Abate, ...
    The Lancet Neurology 18 (5), 439-458 2019
    Citations: 1534

  • Cancer incidence, mortality, years of life lost, years lived with disability, and disability-adjusted life years for 29 cancer groups from 2010 to 2019: a systematic analysis
    JM Kocarnik, K Compton, FE Dean, W Fu, BL Gaw, JD Harvey, ...
    JAMA oncology 8 (3), 420-444 2022
    Citations: 1262

  • Global burden of 369 diseases and injuries in 204 countries and territories, 1990–2019: a systematic analysis for the Global Burden of Disease Study 2019
    C Abbafati, DB Machado, B Cislaghi, OM Salman, M Karanikolos, ...
    Deakin University 2020
    Citations: 1173

  • Global, regional, and national age-sex-specific mortality and life expectancy, 1950–2017: a systematic analysis for the Global Burden of Disease Study 2017
    D Dicker, G Nguyen, D Abate, KH Abate, SM Abay, C Abbafati, N Abbasi, ...
    The lancet 392 (10159), 1684-1735 2018
    Citations: 1001